123 Street, NYC, US 0123456789 [email protected]

爱上海,上海419论坛,上海龙凤419 - Powered by Makenna Bufu!

nzvyhjpnc

first_img Andy Ross | Wednesday, 29th January, 2020 | More on: GSK SMDS “This Stock Could Be Like Buying Amazon in 1997” Our 6 ‘Best Buys Now’ Shares One of the big disadvantages with buy-to-let investing is that it can be hard work. Washing machines break, pipes leak and some tenants don’t want to pay rent if they can possibly avoid it. And with government tax changes pushing down the returns that can be made, I think it makes sense for many to put money into the stock market instead this year.Here are two shares I think have the potential to grow without too many ups and downs, helping investors make a healthy return, minus the buy-to-let headaches.5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…Ploughing money into new drugsGlaxoSmithKline (LSE: GSK) has had to respond in recent years to the loss of patents on some of its major drugs. Arguably the response was too slow, but this is changing – fast.Now GSK has 12 drugs at stage III trials – the final stage before registration. It has a further 22 drugs are at stage II as well. But although that may sound impressive, its main FTSE 100 rival, AstraZeneca, has 27 drugs at stage III and 47 at stage II. There’s a clear gulf between the two companies, but it doesn’t mean GSK is in a bad position. It’s just not as strong on the development front currently. It has advantages too. A dividend yield of 4.5% far outstrips the yield on offer from its rival, which is below 3%. At the same time, GSK is also far cheaper. Its P/E of 15 is much better value than AstraZeneca’s, which is nearer 30.If the moves GSK is making to improve its R&D are effective while it spins out its consumer business, then the group could reward shareholders very nicely. I think the upside means the share shouldn’t have investors reaching for the aspirin.Ditching plasticDS Smith (LSE: SMDS) has, I think, been unfairly caught up in the consumer backlash against plastic. As a packaging company, it is associated with plastic, but management has sold the plastics division. A global partnership with the Ellen MacArthur Foundation – a leader in pushing for a circular economy – shows management is taking sustainability seriously. Yet the shares are quite cheap on a P/E of only 10.The dividend yield of 4.5% is just about in line with the FTSE 100 average and its historical dividend cover has tended to be over two, which is a good indicator of the sustainability of the dividend. Put another way, a cut doesn’t seem imminent unless earnings drop rapidly for a sustained period. The dividend has also tended to grow most years, except for a slight blip in 2018.The low P/E, combined with the high dividend yield, means I’d be tempted to pick up the shares if the market falls back from its recent highs.I think that for investors who don’t want to spend a lot of time researching lots of shares and don’t want to hold anything that’s too volatile, these two are a good fit. The businesses have many strengths and I feel they should be steady performers in the years ahead. Forget buy-to-let! I’d buy these two shares for an easy life I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. Simply click below to discover how you can take advantage of this. I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.center_img Image source: Getty Images. Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. Andy Ross owns shares in AstraZeneca. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended DS Smith. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! Enter Your Email Address See all posts by Andy Rosslast_img read more